TScan Therapeutics, Inc. Share Price
TCRXTScan Therapeutics, Inc. Stock Performance
Open $1.02 | Prev. Close $1.05 | Circuit Range N/A |
Day Range $1.01 - $1.10 | Year Range $0.91 - $4.85 | Volume 19,281 |
Average Traded $1.05 |
TScan Therapeutics, Inc. Share Price Chart
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TScan Therapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
04-Dec-25 | $1.02 | $1.09 | +0.00% |
04-Dec-25 | $1.02 | $1.09 | +13.90% |
02-Dec-25 | $1.00 | $0.96 | -7.54% |
01-Dec-25 | $1.11 | $1.03 | -7.59% |
28-Nov-25 | $1.16 | $1.12 | +0.90% |
26-Nov-25 | $1.02 | $1.11 | +13.38% |
25-Nov-25 | $0.97 | $0.98 | +1.03% |